CROs offering Immunogenicity Assays (ADA / NAb) with Peptide
8 published
8 published CROs match Immunogenicity Assays (ADA / NAb) and Peptide.
Locations in this set include United States, China, India, United Kingdom, Australia, and Belgium.
Capabilities that show up most often in this set: Bioanalysis, Biomarker Assays, Flow Cytometry Services, In Vivo PK / PD Studies, and LC-MS Bioanalysis (Small Molecule).
Matching companies
Amador BioscienceAmador Bioscience provides bioanalysis and biomarker services, including LCMS, immunoassays, flow cytometry, and immunogenicity testing, alongside clinical pharmacology modeling and regulatory affairs support. Its labs are GLP compliant, and its teams work across the US, China, and Europe.
Aragen Life SciencesGlobal CRDMO partner offering integrated discovery-to-commercialization services across small molecules and biologics, with 4000+ scientists and R&D/manufacturing campuses in Asia, North America, and Europe.
BioDuro-SundiaBioDuro-Sundia is a contract research, development, and manufacturing organization (CRDMO) with 30 years of expertise providing integrated drug discovery, development, and manufacturing services from target identification through IND submission.
ChemPartnerGlobal preclinical CRO with 20+ years of experience supporting drug discovery through IND submission across small molecules and biologics, with 2,000+ scientists and facilities worldwide.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.- Swiss BioQuant AGBioanalytical CRO offering LC-MS/MS and ligand-binding assay development, validation, and sample analysis for small and large molecules. Work runs in a 21 CFR Part 11 compliant environment, with qPCR support for gene therapy bioanalysis.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
WuXi AppTecGlobal CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Markdown mirror: /explore/immunogenicity-assays/peptide.md